JS 207
Alternative Names: JS-207Latest Information Update: 06 Mar 2024
At a glance
- Originator DotBio
- Developer Shanghai Junshi Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 07 Sep 2023 NMPA approves IND application for JS 207 in Solid tumours
- 01 Sep 2023 Shanghai Junshi Bioscience in collaboration with GmbH plans a phase I trial for Solid tumour (Late stage disease) in China (IV)(NCT06022250)
- 05 Jan 2023 Shanghai Junshi Biosciences in-licenses DotBody modules from DotBio